{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:48:28Z","timestamp":1770518908167,"version":"3.49.0"},"reference-count":48,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,2,4]]},"DOI":"10.1248\/bpb.b25-00491","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T22:08:04Z","timestamp":1770156484000},"page":"220-228","source":"Crossref","is-referenced-by-count":0,"title":["The NAMPT Inhibitor FK866 Attenuates DEN-Induced Liver Fibrosis in Mice"],"prefix":"10.1248","volume":"49","author":[{"given":"Daocun","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Hospital Affiliated to Army Medical University, Chongqing 400038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Health Management Centre, Chongqing General Hospital, Chongqing 401147, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Fan","sequence":"additional","affiliation":[{"name":"Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing 400016, China"},{"name":"Department of Pathophysiology, Basic Medical College, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingnan","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing 400016, China"},{"name":"Department of Pathophysiology, Basic Medical College, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longjiang","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing 400016, China"},{"name":"Department of Pathophysiology, Basic Medical College, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Byass P. The global burden of liver disease: a challenge for methods and for public health. <i>BMC Med.<\/i>, <b>12<\/b>, 159 (2014).","DOI":"10.1186\/s12916-014-0159-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. <i>Nat. Rev. Gastroenterol. Hepatol.<\/i>, <b>18<\/b>, 151\u2013166 (2021).","DOI":"10.1038\/s41575-020-00372-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Huisman TM, Dieterich DT, Friedman SL. Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update. <i>J. Exp. Pharmacol.<\/i>, <b>13<\/b>, 329\u2013338 (2021).","DOI":"10.2147\/JEP.S265286"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ma J-Q, Ding J, Zhang L, Liu C-M. Protective effects of ursolic acid in an experimental model of liver fibrosis through Nrf2\/ARE pathway. <i>Clin. Res. Hepatol. Gastroenterol.<\/i>, <b>39<\/b>, 188\u2013197 (2015).","DOI":"10.1016\/j.clinre.2014.09.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. <i>Nat. Rev. Gastroenterol. Hepatol.<\/i>, <b>20<\/b>, 633\u2013646 (2023).","DOI":"10.1038\/s41575-023-00807-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. <i>J. Clin. Invest.<\/i>, <b>113<\/b>, 1318\u20131327 (2004).","DOI":"10.1172\/JCI200419930"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Meier FMP, Frommer KW, Peters MA, Brentano F, Lef\u00e8vre S, Schr\u00f6der D, Kyburz D, Steinmeyer J, Rehart S, Gay S, M\u00fcller-Ladner U, Neumann E. Visfatin\/Pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. <i>J. Biol. Chem.<\/i>, <b>287<\/b>, 28378\u201328385 (2012).","DOI":"10.1074\/jbc.M111.312884"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin\/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. <i>Metabolism<\/i>, <b>60<\/b>, 63\u201370 (2011).","DOI":"10.1016\/j.metabol.2010.04.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. <i>J. Immunol.<\/i>, <b>178<\/b>, 1748\u20131758 (2007).","DOI":"10.4049\/jimmunol.178.3.1748"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Starr AE, Deeke SA, Ning Z, Chiang C-K, Zhang X, Mottawea W, Singleton R, Benchimol EI, Wen M, Mack DR, Stintzi A, Figeys D. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn\u2019s disease from UC. <i>Gut<\/i>, <b>66<\/b>, 1573\u20131583 (2017).","DOI":"10.1136\/gutjnl-2015-310705"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Elhassan YS, Philp AA, Lavery GG. Targeting NAD<sup>+<\/sup> in metabolic disease: new insights into an old molecule. <i>J. Endocr. Soc.<\/i>, <b>1<\/b>, 816\u2013835 (2017).","DOI":"10.1210\/js.2017-00092"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Okabe K, Yaku K, Tobe K, Nakagawa T. Implications of altered NAD metabolism in metabolic disorders. <i>J. Biomed. Sci.<\/i>, <b>26<\/b>, 34 (2019).","DOI":"10.1186\/s12929-019-0527-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Amjad S, Nisar S, Bhat AA, Shah AR, Frenneaux MP, Fakhro K, Haris M, Reddy R, Patay Z, Baur J, Bagga P. Role of NAD<sup>+<\/sup> in regulating cellular and metabolic signaling pathways. <i>Mol. Metab.<\/i>, <b>49<\/b>, 101195 (2021).","DOI":"10.1016\/j.molmet.2021.101195"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Goikoetxea-Usandizaga N, Bravo M, Egia-Mendikute L, <i>et al<\/i>. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent. <i>Hepatology<\/i>, <b>78<\/b>, 878\u2013895 (2023).","DOI":"10.1097\/HEP.0000000000000303"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the <i>in vivo<\/i> evidence. <i>Cell Metab.<\/i>, <b>27<\/b>, 529\u2013547 (2018).","DOI":"10.1016\/j.cmet.2018.02.011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yaku K, Okabe K, Nakagawa T. NAD metabolism: implications in aging and longevity. <i>Ageing Res. Rev.<\/i>, <b>47<\/b>, 1\u201317 (2018).","DOI":"10.1016\/j.arr.2018.05.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Travelli C, Colombo G, Mola S, Genazzani AA, Porta C. NAMPT: a pleiotropic modulator of monocytes and macrophages. <i>Pharmacol. Res.<\/i>, <b>135<\/b>, 25\u201336 (2018).","DOI":"10.1016\/j.phrs.2018.06.022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Wang L-F, Wang X-N, Huang C-C, Hu L, Xiao Y-F, Guan X-H, Qian Y-S, Deng K-Y, Xin H-B. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1\/AMPK\u03b1\/SREBP1 signaling pathway. <i>Lipids Health Dis.<\/i>, <b>16<\/b>, 82 (2017).","DOI":"10.1186\/s12944-017-0464-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY. Hepatic NAD<sup>+<\/sup> deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. <i>Br. J. Pharmacol.<\/i>, <b>173<\/b>, 2352\u20132368 (2016).","DOI":"10.1111\/bph.13513"},{"key":"20","unstructured":"20) Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. <i>Cancer Res.<\/i>, <b>63<\/b>, 7436\u20137442 (2003)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR. NAD metabolism fuels human and mouse intestinal inflammation. <i>Gut<\/i>, <b>67<\/b>, 1813\u20131823 (2018).","DOI":"10.1136\/gutjnl-2017-314241"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Matsuda A, Yang W-L, Jacob A, Aziz M, Matsuo S, Matsutani T, Uchida E, Wang P. FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice <i>via<\/i> NF-\u03baB pathway. <i>Ann. Surg.<\/i>, <b>259<\/b>, 1007\u20131017 (2014).","DOI":"10.1097\/SLA.0000000000000329"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Esposito E, Impellizzeri D, Mazzon E, Fakhfouri G, Rahimian R, Travelli C, Tron GC, Genazzani AA, Cuzzocrea S. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. <i>J. Neuroinflammation<\/i>, <b>9<\/b>, 66 (2012).","DOI":"10.1186\/1742-2094-9-66"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Franco-Trepat E, Alonso-P\u00e9rez A, Guill\u00e1n-Fresco M, Jorge-Mora A, Gualillo O, G\u00f3mez-Reino JJ, G\u00f3mez Bahamonde R. Visfatin as a therapeutic target for rheumatoid arthritis. <i>Expert Opin. Ther. Targets<\/i>, <b>23<\/b>, 607\u2013618 (2019).","DOI":"10.1080\/14728222.2019.1617274"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Druckrey H, Preussmann R, Ivankovic S, Schm\u00e4hl D, Afkham J, Blum G, Mennel HD, M\u00fcller M, Petropoulos P, Schneider H. Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. <i>J. Cancer Res. Clin. Oncol.<\/i>, <b>69<\/b>, 103\u2013201 (1967).","DOI":"10.1007\/BF00524152"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tanaka M, Miyajima A. Liver regeneration and fibrosis after inflammation. <i>Inflamm. Regen.<\/i>, <b>36<\/b>, 19 (2016).","DOI":"10.1186\/s41232-016-0025-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Verna L, Whysner J, Williams GM. N-Nitrosodiethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. <i>Pharmacol. Ther.<\/i>, <b>71<\/b>, 57\u201381 (1996).","DOI":"10.1016\/0163-7258(96)00062-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Nasr SM, Hassan M, Abou-Shousha T, Elhusseny Y, Elzallat M. Effect of placental derived nucleoproteins on liver regeneration in DEN-induced liver fibrosis model. <i>Biomed. Pharmacother.<\/i>, <b>178<\/b>, 117190 (2024).","DOI":"10.1016\/j.biopha.2024.117190"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. <i>Lab. Anim.<\/i>, <b>49<\/b> (Suppl.), 59\u201369 (2015).","DOI":"10.1177\/0023677215570086"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Van Gool F, Gall\u00ed M, Gueydan C, Kruys V, Prevot P-P, Bedalov A, Mostoslavsky R, Alt FW, De Smedt T, Leo O. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. <i>Nat. Med.<\/i>, <b>15<\/b>, 206\u2013210 (2009).","DOI":"10.1038\/nm.1906"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase\/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. <i>PLoS One<\/i>, <b>3<\/b>, e2267 (2008).","DOI":"10.1371\/journal.pone.0002267"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D\u2019Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A. Catastrophic NAD<sup>+<\/sup> depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. <i>PLoS One<\/i>, <b>4<\/b>, e7897 (2009).","DOI":"10.1371\/journal.pone.0007897"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver Int.<\/i>, <b>38<\/b> (Suppl. 1), 2\u20136 (2018).","DOI":"10.1111\/liv.13682"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. <i>Mol. Aspects Med.<\/i>, <b>65<\/b>, 37\u201355 (2019).","DOI":"10.1016\/j.mam.2018.09.002"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. <i>J. Hepatol.<\/i>, <b>58<\/b>, 593\u2013608 (2013).","DOI":"10.1016\/j.jhep.2012.12.005"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. <i>Nat. Rev. Immunol.<\/i>, <b>14<\/b>, 181\u2013194 (2014).","DOI":"10.1038\/nri3623"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ozen C, Yildiz G, Dagcan AT, Cevik D, Ors A, Keles U, Topel H, Ozturk M. Genetics and epigenetics of liver cancer. <i>N. Biotechnol.<\/i>, <b>30<\/b>, 381\u2013384 (2013).","DOI":"10.1016\/j.nbt.2013.01.007"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Erener S, Mirsaidi A, Hesse M, Tiaden AN, Ellingsgaard H, Kostadinova R, Donath MY, Richards PJ, Hottiger MO. ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation. <i>FASEB J.<\/i>, <b>26<\/b>, 2631\u20132638 (2012).","DOI":"10.1096\/fj.11-200212"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Erener S, Hesse M, Kostadinova R, Hottiger MO. Poly(ADP-ribose)polymerase-1 (PARP1) controls adipogenic gene expression and adipocyte function. <i>Mol. Endocrinol.<\/i>, <b>26<\/b>, 79\u201386 (2012).","DOI":"10.1210\/me.2011-1163"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Bai P, Canto C, Bruny\u00e1nszki A, Huber A, Sz\u00e1nt\u00f3 M, Cen Y, Yamamoto H, Houten SM, Kiss B, Oudart H, Gergely P, Menissier-de Murcia J, Schreiber V, Sauve AA, Auwerx J. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. <i>Cell Metab.<\/i>, <b>13<\/b>, 450\u2013460 (2011).","DOI":"10.1016\/j.cmet.2011.03.013"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Bai P, Cant\u00f3 C, Oudart H, Bruny\u00e1nszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper Riekelt H, Schoonjans K, Schreiber V, Sauve Anthony A, Menissier-de Murcia J, Auwerx J. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. <i>Cell Metab.<\/i>, <b>13<\/b>, 461\u2013468 (2011).","DOI":"10.1016\/j.cmet.2011.03.004"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Mukhopadhyay P, Rajesh M, Cao Z, Horv\u00e1th B, Park O, Wang H, Erdelyi K, Holovac E, Wang Y, Liaudet L, Hamdaoui N, Lafdil F, Hask\u00f3 G, Szabo C, Boulares AH, Gao B, Pacher P. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. <i>Hepatology<\/i>, <b>59<\/b>, 1998\u20132009 (2014).","DOI":"10.1002\/hep.26763"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases. mechanism and clinical study. <i>Signal Transduct. Target. Ther.<\/i>, <b>5<\/b>, 209 (2020).","DOI":"10.1038\/s41392-020-00312-6"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Billingham LK, Chandel NS. NAD-biosynthetic pathways regulate innate immunity. <i>Nat. Immunol.<\/i>, <b>20<\/b>, 380\u2013382 (2019).","DOI":"10.1038\/s41590-019-0353-x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Cameron AM, Castoldi A, Sanin DE, Flachsmann LJ, Field CS, Puleston DJ, Kyle RL, Patterson AE, H\u00e4ssler F, Buescher JM, Kelly B, Pearce EL, Pearce EJ. Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage. <i>Nat. Immunol.<\/i>, <b>20<\/b>, 420\u2013432 (2019).","DOI":"10.1038\/s41590-019-0336-y"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Rahman MDH, Biswas P, Dey D, Hannan MA, Sahabuddin M, Araf Y, Kwon Y, Emran TB, Ali MS, Uddin MJ. An in-silico identification of potential flavonoids against kidney fibrosis targeting TGF\u03b2R-1. <i>Life<\/i>, <b>12<\/b>, 1764 (2022).","DOI":"10.3390\/life12111764"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Budi EH, Schaub JR, Decaris M, Turner S, Derynck R. TGF-\u03b2 as a driver of fibrosis. physiological roles and therapeutic opportunities. <i>J. Pathol.<\/i>, <b>254<\/b>, 358\u2013373 (2021).","DOI":"10.1002\/path.5680"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Huang H, Wei S, Wu X, Zhang M, Zhou B, Huang D, Dong W. Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>464<\/b>, 116438 (2023).","DOI":"10.1016\/j.taap.2023.116438"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00491\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:31:49Z","timestamp":1770435109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00491\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00491","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"b25-00491"}}